Literature DB >> 33619196

Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data.

Karoline Freeman1, Sian Taylor-Phillips2, Brian H Willis3, Ronan Ryan3, Aileen Clarke2.   

Abstract

OBJECTIVE: To estimate the test accuracy of faecal calprotectin (FC) for inflammatory bowel disease (IBD) in the primary care setting using routine electronic health records.
DESIGN: Retrospective cohort test accuracy study.
SETTING: UK primary care. PARTICIPANTS: 5970 patients (≥18 years) without a previous IBD diagnosis and with a first FC test between 1 January 2006 and 31 December 2016. We excluded multiple tests and tests without numeric results in units of µg/g. INTERVENTION: FC testing for the diagnosis of IBD. Disease status was confirmed by a recorded diagnostic code and/or a drug code of an IBD-specific medication at three time points after the FC test date. MAIN OUTCOME MEASURES: Sensitivity, specificity, and positive and negative predictive values for the differential of IBD versus non-IBD and IBD versus irritable bowel syndrome (IBS) at the 50 and 100 µg/g thresholds.
RESULTS: 5970 patients met the inclusion criteria and had at least 6 months of follow-up data after FC testing. 1897 had an IBS diagnosis, 208 had an IBD diagnosis, 31 had a colorectal cancer diagnosis, 80 had more than one diagnosis and 3754 had no subsequent diagnosis. Sensitivity, specificity, and positive and negative predictive values were 92.9% (88.6% to 95.6%), 61.5% (60.2% to 62.7%), 8.1% (7.1% to 9.2%) and 99.6% (99.3% to 99.7%), respectively, at the threshold of 50 µg/g. Raising the threshold to 100 µg/g missed less than 7% additional IBD cases. Longer follow-up had no effect on test accuracy. Overall, uncertainty was greater for specificity than sensitivity. General practitioners' (GPs') referral decisions did not follow the anticipated clinical pathways in national guidance.
CONCLUSIONS: GPs can be confident in excluding IBD on the basis of a negative FC test in a population with low pretest risk but should interpret a positive test with caution. The applicability of national guidance to general practice needs to be improved. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  gastroenterology; inflammatory bowel disease; primary care

Year:  2021        PMID: 33619196      PMCID: PMC7903095          DOI: 10.1136/bmjopen-2020-044177

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  29 in total

Review 1.  Indeterminate colitis.

Authors:  Karel Geboes; Gert De Hertogh
Journal:  Inflamm Bowel Dis       Date:  2003-09       Impact factor: 5.325

Review 2.  Development of practical recommendations for diagnostic accuracy studies in low-prevalence situations.

Authors:  Gea A Holtman; Marjolein Y Berger; Huibert Burger; Jonathan J Deeks; Norbert Donner-Banzhoff; Thomas R Fanshawe; Constantinos Koshiaris; Mariska M Leeflang; Jason L Oke; Rafael Perera; Johannes B Reitsma; Ann Van den Bruel
Journal:  J Clin Epidemiol       Date:  2019-05-28       Impact factor: 6.437

3.  Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease.

Authors:  Maxime M W De Sloovere; Dieter De Smet; Filip J Baert; Johan Debrabandere; Hilde J M Vanpoucke
Journal:  Clin Chem Lab Med       Date:  2017-08-28       Impact factor: 3.694

Review 4.  A contemporary and critical appraisal of 'indeterminate colitis'.

Authors:  Robert D Odze
Journal:  Mod Pathol       Date:  2015-01       Impact factor: 7.842

5.  Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease.

Authors:  Delphine Labaere; Annick Smismans; August Van Olmen; Paul Christiaens; Geert D'Haens; Veerle Moons; Pieter-Jan Cuyle; Johan Frans; Peter Bossuyt
Journal:  United European Gastroenterol J       Date:  2014-02       Impact factor: 4.623

6.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.

Authors:  Betina T Blak; Mary Thompson; Hassy Dattani; Alison Bourke
Journal:  Inform Prim Care       Date:  2011

7.  The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.

Authors:  Sarita Shrestha; Ola Olén; Carl Eriksson; Åsa H Everhov; Pär Myrelid; Isabella Visuri; Jonas F Ludvigsson; Ida Schoultz; Scott Montgomery; Michael C Sachs; Jonas Halfvarson; Malin Olsson; Henrik Hjortswang; Jonas Bengtsson; Hans Strid; Marie Andersson; Susanna Jäghult; Michael Eberhardson; Caroline Nordenvall; Jan Björk; Ulrika L Fagerberg; Martin Rejler; Olof Grip; Pontus Karling; Mattias Block; Eva Angenete; Per M Hellström; Anders Gustavsson
Journal:  Scand J Gastroenterol       Date:  2020-05-06       Impact factor: 2.423

8.  Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Robyn Wilson; Francis A Carey; Callum G Fraser; Robert J C Steele
Journal:  Gut       Date:  2015-08-20       Impact factor: 23.059

9.  Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study.

Authors:  Evangelos Kontopantelis; Richard John Stevens; Peter J Helms; Duncan Edwards; Tim Doran; Darren M Ashcroft
Journal:  BMJ Open       Date:  2018-02-28       Impact factor: 2.692

10.  Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway.

Authors:  James Turvill; Daniel Turnock; Hayden Holmes; Alison Jones; Eleanor Mclaughlan; Victoria Hilton; Stacey Marriott
Journal:  Frontline Gastroenterol       Date:  2018-06-07
View more
  2 in total

Review 1.  Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease.

Authors:  Karoline Freeman; Brian H Willis; Ronan Ryan; Sian Taylor-Phillips; Aileen Clarke
Journal:  BMC Med Res Methodol       Date:  2022-07-12       Impact factor: 4.612

2.  Faecal calprotectin testing in UK general practice: a retrospective cohort study using The Health Improvement Network database.

Authors:  Karoline Freeman; Ronan Ryan; Nicholas Parsons; Sian Taylor-Phillips; Brian H Willis; Aileen Clarke
Journal:  Br J Gen Pract       Date:  2021-10-28       Impact factor: 5.386

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.